Company Presentation - Madrigal Pharmaceuticals will present at the 43rd Annual J P Morgan Healthcare Conference on January 15 2025 at 2 15 pm PT [1] - The presentation will be webcast live and accessible via Madrigalâs Investor Relations Site Events and Presentations [1] Company Overview - Madrigal Pharmaceuticals is a biopharmaceutical company focused on developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) a liver disease with significant unmet medical needs [2] - The companyâs lead medication Rezdiffra (resmetirom) is a once-daily oral liver-directed THR-β agonist designed to target key underlying causes of MASH [2] Contact Information - Investor inquiries can be directed to Tina Ventura at IR@madrigalpharma com [3] - Media inquiries can be directed to Christopher Frates at media@madrigalpharma com [3]

Madrigal Pharmaceuticals, Inc. (MDGL) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MDGL's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross."A golden cross is a technical chart pattern that can signify a potential bullish breakout. It's formed from a crossover involving a security's short-term moving average breaking above a longer-term moving average, with the most common moving av ...

Shares of Madrigal (MDGL) have gained 34.6% over the past four weeks to close the last trading session at $288.58, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $364.87 indicates a potential upside of 26.4%.The average comprises 15 short-term price targets ranging from a low of $155 to a high of $507, with a standard deviation of $81.13. While the lowest estimate indicates a d ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even though momentum is a popular stock char ...

CONSHOHOCKEN, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences: UBS Global Healthcare Conference 2024Wednesday, November 13, 2024 at 2:00 P.M. ESTThe presentation will be webcast live and may be accessed here. 7th Annual Evercore HealthCONx ConferenceWednesday, December 4, 2024 at 9:35 A.M. EST Piper Sandler 36th Annual Healthcare ConferenceThursday, December 5, 2024 ...

Madrigal Pharmaceuticals (MDGL) reported third-quarter 2024 loss of $4.92 per share, narrower than the Zacks Consensus Estimate of a loss of $6.94 per share. In the year-ago quarter, the company reported a loss of $5.34 per share.During the quarter, the company generated total revenues of $62.2 million — entirely from product sales of its recently approved nonalcoholic steatohepatitis (NASH) drug Rezdiffra (resmetirom), which was commercially launched this April. The metric beat the Zacks Consensus Estimate ...

Financial Data and Key Metrics Changes - The company reported net sales of $62 million for Q3 2024, reflecting strong demand and exceeding expectations [7][35] - R&D expenses for Q3 2024 were $68.7 million, down from $71 million in Q3 2023, indicating stable R&D spending [39] - SG&A expenses increased to $107.6 million from $27.6 million in Q3 2023, primarily due to the expansion of commercial operations following Rezdiffra's approval [39] - The company had $1 billion in cash and marketable securities as of September 30, 2024, providing a strong financial position to support ongoing operations [40] Business Line Data and Key Metrics Changes - The launch of Rezdiffra has seen over 6,800 patients on the drug by the end of Q3 2024, a significant increase from over 2,000 patients at the end of Q2 2024 [10] - The company achieved coverage for more than 80% of commercial lives for Rezdiffra, ahead of schedule [13] - Approximately 40% of top prescribers have prescribed Rezdiffra, doubling the penetration rate from the previous quarter [17] Market Data and Key Metrics Changes - The company is targeting 315,000 patients diagnosed with NASH with moderate to advanced fibrosis, with only 2% currently on treatment [25] - The market for NASH treatment is expected to expand significantly, with the potential for combination therapies as 25% of Rezdiffra patients are already using it alongside GLP-1s for comorbidities [27] Company Strategy and Development Direction - The company aims to strengthen its leadership position in the NASH market through the successful launch of Rezdiffra and plans for a European launch in the second half of 2025 [29] - The company is focused on building a pipeline beyond Rezdiffra, looking for opportunities in NASH and potential combination therapies [119] - The management emphasizes the importance of establishing Rezdiffra as the foundational therapy for NASH, supported by positive clinical outcomes and real-world data [22][34] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future market dynamics, citing Rezdiffra's strong product profile and the significant opportunity to penetrate the target market [28] - The management noted that the early launch metrics are crucial indicators of future success, with growth tracking well against benchmarks from other successful specialty medicine launches [45] - The company is preparing for potential competition from GLP-1 therapies, which could further accelerate the growth opportunity for Rezdiffra [25][26] Other Important Information - The company completed enrollment in its MAESTRO-NASH OUTCOMES trial, which could position Rezdiffra as the first therapy for patients with compensated NASH cirrhosis [30][31] - The company is enhancing its R&D capabilities with the appointment of Dr. Michael Charlton as Head of Clinical Development, a recognized expert in NASH [32] Q&A Session Summary Question: Future growth expectations for Q4 and 2025 - Management is pleased with the strong launch progress and anticipates growth in Q4 and 2025 based on current performance metrics [44][46] Question: Cadence of new patient starts - The company is steadily adding patients and prescribers, with expectations for continued growth as the market becomes more established [50] Question: Free drug program utilization - Very little free drug was utilized in the recent quarter, indicating strong coverage and access for patients [64] Question: Persistence and default rates for patients - Management is optimistic about early patient persistence but will need more time to quantify specific rates [116] Question: Business development strategy - The company aims to build a pipeline focused on NASH and is open to evaluating new opportunities that align with its leadership position [119]

Table of Contents _________________________ _________________________ _________________________ Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 Par Value Per Share MDGL The NASDAQ Stock Market LLC _________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period e ...

Third-Quarter 2024 Financial Results October 31, 2024 Susan, NASH/MASH patient and advocate NASDAQ: MDGL © 2024 Madrigal Pharmaceuticals. All rights reserved. Forward-Looking Statements This presentation includes "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, that are based on Madrigal's beliefs and assumptions and on information currently available to it but are subject to factors beyond its control. Forward-looking statemen ...

CONSHOHOCKEN, Pa., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH), today announced multiple resmetirom data presentations at the upcoming American Association for the Study of Liver Diseases (AASLD) Liver Meeting, taking place from November 15-19, 2024 in San Diego. Bill Sibold, Chief Executive Officer of Madriga ...